Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M (up 38.5% year over year) with net income of −$27M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- +38.5% YoY · −45.0% QoQ
- Net income
- −$27M
- −13.5% YoY · −120.3% QoQ
- Operating margin
- -258.3%
Source: XBRL data from the Monte Rosa Therapeutics, Inc. (GLUE) Q3 2025 10-Q on SEC EDGAR. USD.
Monte Rosa Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes identified; provided excerpt contains financial statements and notes rather than Item 1A risk factors
- Liquidity risk: cash, cash equivalents, and marketable securities of $391.3 million expected to fund operations for at least 12 months
- Financing risk: additional funding required for future discovery, preclinical, and clinical activities
- Operational risk: accumulated deficit of $431.1 million with continued operating losses expected as product candidates advance
- Collaboration risk: Roche agreement permits termination in entirety, by country, or by target
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monte Rosa Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.